Uses of thymopeptide alpha1 in pulmonary fibrosis drug preparation

Abstract

The present invention belongs to the technical field of medicine, and relates to new medicinal uses of thymopeptide alpha1, specifically to uses of thymopeptide alpha1 in pulmonary fibrosis drug preparation. Based on disadvantages of extremely poor prognosis, no effective treatment method, extremely high death rate and the like in idiopathic pulmonary fibrosis treatment by using the existing drugs, a strategy for targeted Th1 type reaction increase or Th2 type reaction inhibition is adopted, thymopeptide alpha1 is adopted as an immune modulator to increase the Th1 type immune reaction and other immune modulation effects, and animal experiment results show that immune disbalance of the pulmonary fibrosis body can be corrected with the thymopeptide alpha1, infection incidence rate can be significantly reduced, and death rate can be reduced, such that the thymopeptide alpha1 can further be used for preparation of pulmonary fibrosis drugs. According to the present invention, under the status of lack of effective pulmonary fibrosis disease treatment drugs, important clinical values are provided, and reliable experimental basis is provided for wide clinical applications.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a new medicinal application of thymosin α1, in particular to the application of thymosin α1 (Ridaxian) in the preparation of medicines for treating pulmonary fibrosis. Background technique [0002] So far, the cause of idiopathic pulmonary fibrosis (IPF) is unknown, the pathogenesis is unclear, the prognosis is poor, the 5-year survival rate is less than 50%, and the median survival time after diagnosis is only 2-3 years. The guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis formulated in March 2011 disclosed that the incidence of IPF has shown a clear increase trend, and the mortality rate has increased significantly in the past 20 years, and the mortality rate is higher than that of some cancers. There is still no effective treatment for pulmonary fibrosis. [0003] Adrenal glucocorticoid (referred to as: hormone) has been the main means of IPF treatme...

AI Technical Summary

Problems solved by technology

The guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis formulated in March 2011 disclosed that the incidence of IPF has shown a clear increase trend, and the mortality rate has increased significantly in the past 20 years, and the mortality rate is higher than that of some cancers. There is still no effective treatment for chronic pulmonary fibrosis

One of the reasons is: after using hormones, as time goes on, the side effects of hormones become more and more prominent, and various pathogen infections often occur due to severe impairment of immune function, which aggravates the disease and leads to death. Patients on hormones live shorter

More studies have found that IPF patients themselves are more likely to be aggravated by various pathogenic infections than normal people due to their own immune deficiency

Images